Clinical Trial Update: Study of Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Platinum-based Doublet Chemotherapy as First-line Treatment for Participants With Locally Advanced or Metastatic NSCLC. [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating ociperlimab with tislelizumab and chemotherapy in first-line locally advanced or metastatic non-small cell lung cancer has been withd…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Ociperlimab (ociperlimab)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Non-small Cell Lung Cancer (NSCLC) | Phase 3 | Status: WITHDRAWN